• Overview
  • Eligibility
  • More info
  • Locations

Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma (NCT00003677)

National Cancer Institute (NCI)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients who have metastatic pancreatic cancer.
  • Drug: Dolastatin 10
    IV bolus once every 21 days.
    Ages eligible for Study
    18 Years and older
    Genders eligible for Study
    Accepts Healthy Volunteers
    OBJECTIVES: I. Assess the antitumor activity of dolastatin 10 in patients with metastatic adenocarcinoma of the pancreas. II. Evaluate the qualitative and quantitative toxic effects of this therapy in these patients. III. Investigate the clinical pharmacology of this treatment.

    OUTLINE: This is an open label, multicenter study. Patients receive dolastatin 10 IV bolus once every 21 days. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months until death.

    PROJECTED ACCRUAL: This study will accrue 12-37 patients within 18.5 months.

    2 locations

    United States (2)
    • University of Chicago Cancer Research Center
      Not specified
      Chicago, Illinois, United States, 60637
    • University of Texas - MD Anderson Cancer Center
      Not specified
      Houston, Texas, United States, 77030
    28 February, 1999
    26 July, 2012
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!